세계의 고양이용 백신 시장 : 시장 규모, 점유율, 성장 및 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of feline vaccines Market

The global feline vaccines market continues to expand steadily as pet ownership rises and veterinary healthcare becomes more advanced. According to the latest industry analysis, the feline vaccines market size reached USD 1.58 billion in 2024, driven by strong awareness of feline health, growing prevalence of infectious diseases, and the increased role of veterinary clinics and hospitals in preventive healthcare. The market is projected to grow further to USD 1.67 billion in 2025, influenced by expanding pet adoption and growing initiatives to prevent zoonotic diseases. By 2032, the market is expected to reach USD 2.65 billion, due to advancements in vaccine technology and increasing investment by veterinary pharmaceutical companies.

Market Drivers: Rising Cat Ownership and Growing Disease Prevalence

The primary driver supporting market growth is the significant rise in cat ownership worldwide. With households increasingly adopting cats as companion animals, the need for preventive vaccination continues to escalate. In the U.S., for example, around 49 million households owned a cat in 2023-2024, according to the American Pet Products Association. This high ownership level directly fuels the demand for core vaccines such as rabies, FeLV, FVRCP, and others.

Additionally, the prevalence of infectious diseases further strengthens market expansion. A study conducted in southern Italy showed that 73.5% of 328 domestic cats tested positive for feline panleukopenia virus, highlighting the global need for timely vaccination. With such increasing disease incidence, pet owners are more focused on safeguarding their animals through reliable vaccination programs.

Market Restraints: Limited Access in Developing Regions

Despite growth in developed markets, limited access to veterinary care in emerging regions remains a significant restraint. Countries with fewer veterinary professionals and limited vaccination infrastructure face challenges in adopting routine immunization for felines. For instance, Kenya has only 410 veterinarians, making widespread vaccination programs difficult to implement. This ultimately restricts growth potential in low-income regions.

Market Opportunities: Government Initiatives for Feline Immunization

Governments and municipal bodies across countries are increasingly adopting programs to vaccinate domestic and stray cats, creating strong market opportunities. In India, the Nashik Municipal Corporation launched a program in July 2025 to vaccinate stray cats against rabies, reflecting a broader trend of public-health-driven vaccination campaigns. Such initiatives contribute significantly to rising vaccine uptake across regions and are expected to support market value growth toward USD 2.65 billion by 2032.

Market Challenges: Vaccine Hesitancy Among Pet Owners

Vaccine hesitancy, largely driven by concerns about vaccine safety and side effects, continues to challenge market expansion. The American Veterinary Medical Association (AVMA) reported in 2024 that many pet owners remain hesitant about immunization, which creates gaps in vaccine coverage and slows overall market adoption.

Market Trends: Advancements in Vaccine Platforms

A major trend shaping the industry is the rapid development of innovative vaccine platforms such as recombinant and next-generation vaccines. Merck's expansion of the NOBIVAC NXT platform, including NOBIVAC NXT FeLV launched in 2024, highlights growing advancements focused on broader protection, longer immunity, and improved safety profiles. This continuous innovation is expected to drive strong demand between 2025 and 2032.

Regional Insights

North America - Leading Regional Market (USD 0.67 Billion in 2024)

North America accounted for the largest market share of 42.40% in 2024, with a market value of USD 0.67 billion. Strong veterinary healthcare infrastructure, high disposable income, and a large pet population underpin regional leadership. The U.S. remains the dominant country, supported by advanced veterinary guidelines and a robust vaccine distribution network.

Europe

Europe is set for strong growth due to increasing pet population, rising cases of feline diseases, and government-supported vaccination programs. The U.K. alone had 10.8 million pet cats in 2024, boosting vaccine demand.

Asia Pacific

Asia Pacific is projected to exhibit the fastest CAGR, driven by rising cat ownership and growing awareness of feline diseases. Australia reported 4.9 million pet cats in 2024, contributing heavily to regional growth.

Latin America & Middle East & Africa

These regions will experience steady growth due to increasing government-run stray cat vaccination programs and rising awareness of zoonotic risks.

Competitive Landscape

The market is semi-consolidated, with top players including Zoetis Services LLC, Merck & Co., Inc., Elanco, Virbac, Boehringer Ingelheim, Ceva, and Bioveta. These companies invest heavily in R&D, new vaccine platforms, and expanded manufacturing capabilities to sustain market leadership.

Segmentation By Technology

• Inactivated
• Live Attenuated
• Recombinant
• Others

By Disease Type

• Feline Viral Rhinotracheitis
• Rabies
• Feline Leukemia Virus
• Others

By Route of Administration

• Parenteral
• Intranasal

By Distribution Channel

• Veterinary Hospitals
• Veterinary Clinics
• Pharmacies & Drug Stores
• Others

By Region

• North America (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
  • U.S.
  • Canada
• Europe (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Overview of Feline Diseases by Key Countries, By Key Countries/ Region, 2024
• 4.2. Regulatory Scenario by Key Countries/ Region, 2024
• 4.3. Overview of Vaccination for Feline Diseases
• 4.4. New Technology Launches, By Key Players
• 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Feline Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Technology
  • 5.1.1. Inactivated
  • 5.1.2. Live Attenuated
  • 5.1.3. Recombinant
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Disease Type
  • 5.2.1. Feline Viral Rhinotracheitis
  • 5.2.2. Rabies
  • 5.2.3. Feline Leukemia Virus
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Parenteral
  • 5.3.2. Intranasal
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Veterinary Hospitals
  • 5.4.2. Veterinary Clinics
  • 5.4.3. Pharmacies & Drug Stores
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Feline Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Technology
  • 6.1.1. Inactivated
  • 6.1.2. Live Attenuated
  • 6.1.3. Recombinant
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Disease Type
  • 6.2.1. Feline Viral Rhinotracheitis
  • 6.2.2. Rabies
  • 6.2.3. Feline Leukemia Virus
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Parenteral
  • 6.3.2. Intranasal
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Veterinary Hospitals
  • 6.4.2. Veterinary Clinics
  • 6.4.3. Pharmacies & Drug Stores
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Feline Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Technology
  • 7.1.1. Inactivated
  • 7.1.2. Live Attenuated
  • 7.1.3. Recombinant
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Disease Type
  • 7.2.1. Feline Viral Rhinotracheitis
  • 7.2.2. Rabies
  • 7.2.3. Feline Leukemia Virus
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Parenteral
  • 7.3.2. Intranasal
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Veterinary Hospitals
  • 7.4.2. Veterinary Clinics
  • 7.4.3. Pharmacies & Drug Stores
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. Germany
  • 7.5.2. U.K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Feline Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Technology
  • 8.1.1. Inactivated
  • 8.1.2. Live Attenuated
  • 8.1.3. Recombinant
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Disease Type
  • 8.2.1. Feline Viral Rhinotracheitis
  • 8.2.2. Rabies
  • 8.2.3. Feline Leukemia Virus
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Parenteral
  • 8.3.2. Intranasal
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Veterinary Hospitals
  • 8.4.2. Veterinary Clinics
  • 8.4.3. Pharmacies & Drug Stores
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Feline Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Technology
  • 9.1.1. Inactivated
  • 9.1.2. Live Attenuated
  • 9.1.3. Recombinant
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Disease Type
  • 9.2.1. Feline Viral Rhinotracheitis
  • 9.2.2. Rabies
  • 9.2.3. Feline Leukemia Virus
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Parenteral
  • 9.3.2. Intranasal
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Veterinary Hospitals
  • 9.4.2. Veterinary Clinics
  • 9.4.3. Pharmacies & Drug Stores
  • 9.4.4. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Feline Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Technology
  • 10.1.1. Inactivated
  • 10.1.2. Live Attenuated
  • 10.1.3. Recombinant
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Disease Type
  • 10.2.1. Feline Viral Rhinotracheitis
  • 10.2.2. Rabies
  • 10.2.3. Feline Leukemia Virus
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Parenteral
  • 10.3.2. Intranasal
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Veterinary Hospitals
  • 10.4.2. Veterinary Clinics
  • 10.4.3. Pharmacies & Drug Stores
  • 10.4.4. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles (Overview, Technology, SWOT analysis, Recent developments, strategies, financials (based on availability)
  • 11.2.1. Elanco
  • 11.2.2. Boehringer Ingelheim International GmbH
  • 11.2.3. Virbac
  • 11.2.4. Merck & Co., Inc.
  • 11.2.5. Zoetis Services LLC
  • 11.2.6. Ceva
  • 11.2.7. Bioveta, a.s.